The U.S. Food and Drug Administration (FDA) has issued a new boxed warning along with a safety communication concerning Adzynma, an enzyme replacement therapy. This update was provided to enhance awareness among patients and healthcare providers about potential risks associated with this treatment.

The FDA's action highlights the occurrence of serious hypersensitivity and other adverse reactions observed with Adzynma. As these reactions pose significant safety concerns, the new warning aims to inform clinical decision-making and patient monitoring strategies during therapy.

Healthcare professionals are advised to carefully evaluate the benefits and risks when considering Adzynma for their patients and to remain vigilant for any signs of hypersensitivity or adverse events. This regulatory communication reinforces the FDA's commitment to ensuring the safe use of biologic therapies.